FDA approves GILD’s Descovy (a/k/a F/TAF), a combination of Emtriva and TAF that GILD hopes will supersede Truvada as the nuke backbone for HIV when added to a third agent:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.